PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31625159-5 2019 METHODS: We examined whether CBD inhibits human CYP3A4 and CYP2C19 mediated metabolism of clobazam and N-desmethylclobazam (N-CLB), respectively, and performed studies assessing the effects of CBD on brain and plasma pharmacokinetics of clobazam in mice. Cannabidiol 29-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 48-54 34330718-11 2021 Significance Statement This study demonstrates that both CYP2C19 and CYP2C9 are involved in CBD metabolism to the active metabolite 7-OH-CBD, and CYP3A4 is a major contributor to CBD metabolism through pathways other than 7-hydroxylation. Cannabidiol 179-182 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 146-152 33635755-14 2020 CBD is hydroxylated to 7-OH-CBD and 7-COOH-CBD by cytochrome P450 enzymes CYP3A4 and CYP2C9 in the liver and is excreted mainly in feces and less in urine. Cannabidiol 0-3 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 74-80 33191836-0 2022 Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. Cannabidiol 110-121 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 125-131 33191836-8 2022 CONCLUSION: CBD at a low dose of 40 mg/day resulted in the potential inhibition of CYP3A4 and/or CYP2D6. Cannabidiol 12-15 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 83-89 32918835-5 2020 Induction of CYP3A4 and CYP2C19 led to small reductions in exposure to CBD and its major metabolites. Cannabidiol 71-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 32918835-6 2020 Inhibition of CYP3A4 activity did not affect CBD exposure and caused small increases in exposure to CBD metabolites. Cannabidiol 100-103 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20 32444381-8 2020 Cannabidiol inhibits CYP3A4 and CYP2C19, both of which are involved in the metabolism of methadone. Cannabidiol 0-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 34918945-6 2021 Objective: Considering the major CES1-mediated metabolism of RDV on systemic administration, we intend to explore the remarkable CES1 plus CYP3A4 inhibitory activity of cannabidiol (CBD) against in vitro microsomal metabolism of RDV to indicate its therapeutic potential as an adjuvant to RDV in the treatment and management of COVID-19. Cannabidiol 169-180 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 139-145 34918945-6 2021 Objective: Considering the major CES1-mediated metabolism of RDV on systemic administration, we intend to explore the remarkable CES1 plus CYP3A4 inhibitory activity of cannabidiol (CBD) against in vitro microsomal metabolism of RDV to indicate its therapeutic potential as an adjuvant to RDV in the treatment and management of COVID-19. Cannabidiol 182-185 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 139-145 34330718-7 2021 CYP3A played a major role in CBD metabolic clearance via oxidation at sites other than the 7-position. Cannabidiol 29-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-5 34121064-8 2021 However, CBD significantly inhibited CYP3A4 and CYP2C19-mediated metabolism of citalopram and its stereoisomer escitalopram at physiologically relevant concentrations, suggesting a possible in vivo DDI. Cannabidiol 9-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-43 31012522-2 2019 CBD is metabolized by cytochrome P450 (CYP)3A4 and CYP2C19 with a growing body of evidence suggesting it is also a potent inhibitor of these pathways. Cannabidiol 0-3 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-46 31433338-8 2019 CYP3A4/5/7 is potentially inhibited by CBD. Cannabidiol 39-42 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 24160757-5 2014 Clinical pharmacogenetic data further support CYP2C9 as a significant contributor to THC metabolism, and a pharmacokinetic interaction study using ketoconazole with oromucosal cannabis extract further supports CYP3A4 as a significant metabolic pathway for THC and CBD. Cannabidiol 264-267 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 210-216 28412920-7 2017 CONCLUSION: THC and CBD are metabolized mainly in the liver by cytochrome P-450 isoenzymes (mainly CYP2Cs and CYP3A4). Cannabidiol 20-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 110-116 28412920-8 2017 In vitro studies indicate that THC and CBD both inhibit CYP1A1, 1A2 and 1B1 enzymes, and recent studies have indicated that CBD is also a potent inhibitor of CYP2C19 and CYP3A4. Cannabidiol 124-127 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 170-176 23750331-10 2013 Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. Cannabidiol 29-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 156-162 21704641-7 2011 Seven of 14 recombinant human CYP enzymes examined (CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) were capable of metabolizing CBD. Cannabidiol 142-145 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 93-99 21356216-7 2011 CBD competitively inhibited the activity of CYP3A4, CYP3A5, and HLMs (K(i)=1.00, 0.195, and 6.14 muM, respectively). Cannabidiol 0-3 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 21356216-10 2011 The lesser inhibitory effects of monomethyl and dimethyl ethers of CBD indicated that the ability of CYP3A inhibition by the cannabinoid attenuated with the number of methylation on the phenolic hydroxyl groups in the resorcinol moiety. Cannabidiol 67-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-106 21356216-11 2011 SIGNIFICANCE: This study indicated that CBD most potently inhibited catalytic activity of human CYP3A enzymes, especially CYP3A4 and CYP3A5. Cannabidiol 40-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-101 21356216-11 2011 SIGNIFICANCE: This study indicated that CBD most potently inhibited catalytic activity of human CYP3A enzymes, especially CYP3A4 and CYP3A5. Cannabidiol 40-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 122-128 21356216-12 2011 These results suggest that two phenolic hydroxyl groups in the resorcinol moiety of CBD may play an important role in the CYP3A inhibition. Cannabidiol 84-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 122-127